These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 24786391)

  • 21. The Development of Epigenetics in the Study of Disease Pathogenesis.
    Jeffries MA
    Adv Exp Med Biol; 2020; 1253():57-94. PubMed ID: 32445091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of 'epidrugs'.
    Cardoso AR; Lobo J; Miranda-Gonçalves V; Henrique R; Jerónimo C
    Epigenetics; 2021 Apr; 16(4):353-372. PubMed ID: 32749176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of epigenetic alterations in human thoracic malignancies: epigenetic alterations in lung cancer.
    Shinjo K; Kondo Y
    Methods Mol Biol; 2012; 863():221-39. PubMed ID: 22359296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells.
    Foltankova V; Legartova S; Kozubek S; Bartova E
    Neoplasma; 2012; 59(4):450-62. PubMed ID: 22489701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
    Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
    Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation.
    Chatonnet F; Pignarre A; Sérandour AA; Caron G; Avner S; Robert N; Kassambara A; Laurent A; Bizot M; Agirre X; Prosper F; Martin-Subero JI; Moreaux J; Fest T; Salbert G
    Haematologica; 2020 Mar; 105(3):774-783. PubMed ID: 31221779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic Modifications in Neurological Diseases: Natural Products as Epigenetic Modulators a Treatment Strategy.
    Gangisetty O; Murugan S
    Adv Neurobiol; 2016; 12():1-25. PubMed ID: 27651245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic signatures in gastric cancer: current knowledge and future perspectives.
    Sogutlu F; Pekerbas M; Biray Avci C
    Expert Rev Mol Diagn; 2022 Dec; 22(12):1063-1075. PubMed ID: 36522183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
    Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
    J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer epigenetics: above and beyond.
    Brait M; Sidransky D
    Toxicol Mech Methods; 2011 May; 21(4):275-88. PubMed ID: 21495866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the epigenetics of fibroblast biology and fibrotic diseases.
    Ulukan B; Sila Ozkaya Y; Zeybel M
    Curr Opin Pharmacol; 2019 Dec; 49():102-109. PubMed ID: 31731224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
    Cacabelos R
    Drug Dev Res; 2014 Sep; 75(6):348-65. PubMed ID: 25195579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrogen sulfide and epigenetics: Novel insights into the cardiovascular effects of this gasotransmitter.
    Spezzini J; Piragine E; d'Emmanuele di Villa Bianca R; Bucci M; Martelli A; Calderone V
    Br J Pharmacol; 2023 Jul; 180(14):1793-1802. PubMed ID: 37005728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
    Dupéré-Richer D; Licht JD
    Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells.
    Jugová A; Sustáčková G; Legartová S; Stixová L; Kozubek S; Bártová E
    Cell Biol Int; 2011 Dec; 35(12):1195-203. PubMed ID: 21635225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetics primer: why the clinician should care about epigenetics.
    Duarte JD
    Pharmacotherapy; 2013 Dec; 33(12):1362-8. PubMed ID: 23864439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetics in breast cancer: what's new?
    Huang Y; Nayak S; Jankowitz R; Davidson NE; Oesterreich S
    Breast Cancer Res; 2011; 13(6):225. PubMed ID: 22078060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenomics in cancer management.
    Costa FF
    Cancer Manag Res; 2010 Oct; 2():255-65. PubMed ID: 21188117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Epigenetic Therapies for Brain Tumors.
    Kukreja L; Li CJ; Ezhilan S; Iyer VR; Kuo JS
    Neuromolecular Med; 2022 Mar; 24(1):41-49. PubMed ID: 34677796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.